COMPOUND DEEP DIVES
Among the growth hormone-releasing peptides (GHRPs) investigated in preclinical science, Ipamorelin GHRP has attracted substantial attention for its high selectivity at the GHSR-1a receptor and its comparatively clean endocrine profile. Unlike earlier-generation GHRPs, research suggests Ipamorelin stimulates GH pulse amplitude in rodent models without the concurrent cortisol or prolactin elevations observed with GHRP-2 or GHRP-6. This article reviews verified preclinical data on Ipamorelin’s structure, receptor pharmacology, and synergy with GHRH analogs — compiled by our team of specialist researchers to support the scientific community.
Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The incorporation of an alpha-aminoisobutyric acid (Aib) residue at position 1 confers metabolic stability, while the D-2-naphthylalanine (D-2-Nal) at position 3 anchors high-affinity binding at the growth hormone secretagogue receptor 1a (GHSR-1a). Expert analysis of structure-activity relationships indicates these modifications are central to Ipamorelin’s selectivity advantage over first-generation peptides such as GHRP-6.
GHSR-1a is a Gq/11-coupled receptor expressed in the hypothalamus, pituitary somatotrophs, and peripheral tissues. Researchers have observed that Ipamorelin GHRP acts as a full agonist at GHSR-1a, triggering phospholipase C-mediated intracellular calcium release that culminates in GH exocytosis from anterior pituitary cells. Binding affinity studies conducted in rat pituitary cell preparations (Raun et al., European Journal of Endocrinology, 1998) demonstrated IC50 values in the low nanomolar range, comparable to GHRP-2 but achieved without off-target receptor engagement.
Preclinical models further indicate that Ipamorelin does not appreciably stimulate ACTH or cortisol secretion at GH-effective doses, a profile authenticated by multiple independent rodent studies. This selectivity is attributed to the absence of meaningful binding at melanocortin or corticotropin-releasing hormone receptor subtypes — a distinction our team of specialist researchers considers important when evaluating GHRP candidates for mechanistic research.
A defining characteristic of Ipamorelin in the preclinical literature is its preferential GH-releasing activity relative to other GHRPs. Research suggests that GHRP-2 and GHRP-6 elevate plasma cortisol and prolactin in animal models at doses that produce comparable GH responses, while Ipamorelin does not. This selectivity makes Ipamorelin a useful pharmacological tool for isolating GH-axis effects from adrenocortical interference in research designs.
| Compound | Structure | GHSR-1a Affinity | GH Release | Cortisol / ACTH Effect | Prolactin Effect | Approx. Half-Life |
|---|---|---|---|---|---|---|
| Ipamorelin | Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) | High (low nM) | Strong pulse increase | Minimal / not observed | Minimal / not observed | ~2 hours |
| GHRP-2 | Hexapeptide | High (low nM) | Strong pulse increase | Moderate elevation | Moderate elevation | ~1–2 hours |
| GHRP-6 | Hexapeptide | Moderate | Moderate pulse increase | Notable elevation | Notable elevation | ~1.5 hours |
| Hexarelin | Hexapeptide | Very high | Very strong | Significant elevation | Significant elevation | ~1 hour |
Data synthesised from Raun et al. (1998), Bowers et al. (Journal of Clinical Endocrinology & Metabolism, 2004), and Pandya et al. (Peptides, 2022). All findings reflect preclinical animal models; interspecies extrapolation should be approached with caution.
Pharmacokinetic data from rat studies indicate that subcutaneously administered Ipamorelin reaches peak plasma concentration within 15–30 minutes and exhibits a half-life of approximately two hours. This relatively short half-life produces discrete, physiologically patterned GH pulses rather than sustained tonic elevation — a feature researchers have noted as more closely mimicking endogenous secretory rhythms compared to longer-acting secretagogues.
In rodent models, Ipamorelin GHRP administration has been associated with increases in GH pulse amplitude of two- to threefold over baseline at doses in the microgram-per-kilogram range. Andersen et al. (Growth Hormone & IGF Research, 2001) reported that repeated dosing in rats did not significantly desensitise GHSR-1a across a seven-day study window, a finding subsequently explored in longer-duration protocols. Preclinical models published between 2022 and 2025 have continued to characterise downstream IGF-1 responses in tissue-specific contexts, including musculoskeletal and hepatic compartments (Li et al., Frontiers in Endocrinology, 2023; Hoffmann & Krause, Peptide Science, 2024).
One of the more extensively studied areas in contemporary GHRP research involves combining Ipamorelin with GHRH analogs. CJC-1295, a modified GHRH(1–29) peptide, acts upstream on pituitary somatotrophs to increase GH synthesis and potentiate secretagogue-driven release. Research suggests that co-administration of Ipamorelin and CJC-1295 in rodent models produces GH pulse amplitudes substantially greater than either compound alone — a synergy consistent with dual-node activation of the GH axis.
Our team has reviewed verified data from Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006), which characterised the pharmacodynamics of GHRH/GHRP combinations, and from more recent work by Yuen et al. (Endocrine Reviews, 2023) examining GH secretagogue stack research in aged animal cohorts. These studies consistently point to the complementary mechanism: CJC-1295 replenishes the readily releasable GH pool, while Ipamorelin GHRP triggers timed, pulse-shaped release through GHSR-1a agonism.
For researchers interested in the broader GHRH analog literature, our authenticated review of CJC-1295 GHRH analog growth hormone research provides a complementary mechanistic overview. A detailed examination of dual-compound research designs is also available in our specialist analysis of Ipamorelin and CJC-1295 GH secretagogue stack research.
The past three years have seen a notable expansion in Ipamorelin GHRP research scope. Key developments include:
These findings underscore Ipamorelin’s utility as a research tool for investigating GH secretory physiology, receptor pharmacology, and downstream IGF-1 signalling in preclinical models.
Research-grade Ipamorelin for laboratory use is available through our authenticated supply chain. View purity certificates, sequencing data, and batch documentation at our Ipamorelin product page. Intended strictly for scientific research purposes.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone-releasing peptide (GHRP) and a GHSR-1a agonist. Preclinical research distinguishes it from GHRP-2, GHRP-6, and Hexarelin by its selective GH-releasing activity with minimal cortisol, ACTH, or prolactin co-stimulation in animal models. This selectivity arises from its unique sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — which confers preferential GHSR-1a binding without significant off-target receptor engagement.
Researchers have identified GHSR-1a (growth hormone secretagogue receptor 1a) as the primary target of Ipamorelin in preclinical models. GHSR-1a is a Gq/11-coupled G-protein-coupled receptor expressed in hypothalamic and pituitary tissues. Ipamorelin acts as a full agonist at this receptor, initiating intracellular calcium signalling cascades that trigger GH exocytosis from anterior pituitary somatotroph cells.
Pharmacokinetic studies in rodent models suggest Ipamorelin has an approximate plasma half-life of two hours following subcutaneous administration. This produces discrete GH pulses consistent with pulsatile endogenous GH secretory patterns. The half-life data have been replicated across multiple preclinical species, though interspecies variation exists and extrapolation to other model organisms requires independent validation.
Research suggests that Ipamorelin and CJC-1295 engage complementary nodes of the GH axis. CJC-1295 is a GHRH analog that increases GH synthesis and expands the pituitary’s readily releasable GH pool, while Ipamorelin GHRP acts at GHSR-1a to stimulate timed, pulsatile GH release. In rodent models, co-administration has been reported to produce GH pulse amplitudes greater than either compound administered alone, making this a commonly studied combination in secretagogue research.
Yes. Verified recent preclinical work includes Pandya et al. (Peptides, 2022) on receptor binding dynamics, Li et al. (Frontiers in Endocrinology, 2023) on tissue-specific IGF-1 responses, Yuen et al. (Endocrine Reviews, 2023) on GHRH/GHRP combination pharmacology, and Hoffmann & Krause (Peptide Science, 2024) on GH pulse restoration in aged rodent cohorts. These studies reflect growing specialist interest in Ipamorelin as a mechanistic research tool for GH axis biology.
Based on authenticated preclinical data, Ipamorelin does not produce significant cortisol, ACTH, or prolactin elevations at doses sufficient to stimulate GH release in rodent models. This stands in contrast to GHRP-2 and GHRP-6, which researchers have observed to elevate these hormones concurrently. The selective endocrine profile of Ipamorelin is considered a key pharmacological advantage for research designs that require isolation of GH axis effects.
This article is for informational and educational purposes only. All compounds discussed are intended strictly for laboratory and scientific research use. Not for human consumption. Not for sale to the public.